driven by the PitchBook Platform
A right of an oral antisense DNA oligonucleotide drug. The asset comprises of phase III trial drug producing assets targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease (CD) and other indications.
This information is reserved for PitchBook Platform users. To explore PhIII Crohn's drug‘s full profile, request access.
© 2018 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.